Overview MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women Status: Completed Trial end date: 2018-11-09 Target enrollment: Participant gender: Summary The purpose of this study is to assess the efficacy and safety of MT-8554 for treatment of vasomotor symptoms (VMS) associated with menopause. Phase: Phase 2 Details Lead Sponsor: Mitsubishi Tanabe Pharma Development America, Inc.